Search

Your search keyword '"Jose Francisco Cabre Marquez"' showing total 3 results
Start Over Author "Jose Francisco Cabre Marquez"
3 results on '"Jose Francisco Cabre Marquez"'

1. Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis

Author

Jamie O’Hara, Ceri Hirst, Jose Francisco Cabre Marquez, and Tom Burke

Subjects
Hemophilia A, Kovaltry, Real world evidence, Factor utilization, Clinical burden, Medicine
Abstract

Abstract Background Untreated hemophilia A patients may experience recurrent bleeding events leading to debilitating joint damages. While RCT and pharmacokinetic data support the value of Kovaltry [an unmodified full-length recombinant factor VIII (FVIII) product], real world evidence in children is lacking. This report describes a descriptive and multivariate analysis of the effectiveness of Kovaltry in children with hemophilia A in the real-world setting, using data from medical chart abstraction and cross-sectional surveys of physicians, patients, and caregivers. Results Male patients aged

Published
2021
Full Text
View/download PDF

2. Efficacy and safety in patients with haemophilia A switching to octocog alfa ( <scp>BAY</scp> 81–8973): Final results of the global real‐world study, <scp>TAURUS</scp>

Author

Cristina Santoro, Beng Fuh, Phu Quoc Le, Philip Maes, Rubén Berrueco, Eva Maria Mingot‐Castellano, Sylvia von Mackensen, Claudia Tueckmantel, Jose Francisco Cabre‐Marquez, and Michael Wang

Subjects
Factor VIII, drug switching, haemophilia A, Hemorrhage, Hematology, General Medicine, Hemophilia A, Treatment Outcome, Humans, octocog alfa, prophylaxis, Prospective Studies, Human medicine, prospective study
Abstract

Objectives To report the final results of the 2-year TAURUS study, assessing weekly prophylaxis dosing regimens of octocog alfa (Kovaltry (R)/BAY 81-8973) used in standard clinical practice in patients with moderate-to-severe haemophilia A. Methods TAURUS (NCT02830477) is a phase 4, multinational, prospective, non-interventional, single-arm study in patients of any age with moderate or severe haemophilia A (= 1

Published
2022

3. Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis

Author

Thomas W. Burke, Ceri Hirst, Jose Francisco Cabre Marquez, and Jamie O'Hara

Subjects
Male, medicine.medical_specialty, Pediatrics, Letter to the editor, Multivariate analysis, lcsh:Medicine, 030204 cardiovascular system & hematology, Real world evidence, Hemophilia A, law.invention, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, hemic and lymphatic diseases, medicine, Humans, Clinical burden, Pharmacology (medical), Adverse effect, Child, Letter to the Editor, Genetics (clinical), Hematology, Factor VIII, business.industry, Medical record, Kovaltry, lcsh:R, General Medicine, Factor utilization, Europe, Cross-Sectional Studies, 030220 oncology & carcinogenesis, business, Cohort study
Abstract

Background Untreated hemophilia A patients may experience recurrent bleeding events leading to debilitating joint damages. While RCT and pharmacokinetic data support the value of Kovaltry [an unmodified full-length recombinant factor VIII (FVIII) product], real world evidence in children is lacking. This report describes a descriptive and multivariate analysis of the effectiveness of Kovaltry in children with hemophilia A in the real-world setting, using data from medical chart abstraction and cross-sectional surveys of physicians, patients, and caregivers. Results Male patients aged Conclusion This analysis demonstrates the effectiveness and safety of Kovaltry in a pan-European pediatric population with severe hemophilia A.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results